Implementation and evaluation of a shared care model between oncologists and pharmacists for breast cancer patients at a Canadian regional ambulatory cancer centre.

IF 1 4区 医学 Q4 ONCOLOGY
Journal of Oncology Pharmacy Practice Pub Date : 2024-06-01 Epub Date: 2023-05-31 DOI:10.1177/10781552231179190
Elaine Goh, Sylvie Labelle, Angela Chan
{"title":"Implementation and evaluation of a shared care model between oncologists and pharmacists for breast cancer patients at a Canadian regional ambulatory cancer centre.","authors":"Elaine Goh, Sylvie Labelle, Angela Chan","doi":"10.1177/10781552231179190","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The introduction of CDK 4/6 inhibitors for breast cancer patients has contributed to increased ambulatory patient visits for oncologists. The Medication Assessment by Pharmacist program aims to evaluate the impact of oncology pharmacists performing medication assessment follow-up visits.</p><p><strong>Methods: </strong>Breast cancer patients on a CDK 4/6 inhibitor deemed suitable by their oncologist for pharmacist assessment could be booked for a pharmacist medication assessment appointment at alternate treatment cycles.</p><p><strong>Results: </strong>Between February 2019 to November 2021, 29 of 128 patients (22.7%) were selected for 46 total Medication Assessment by Pharmacist visits resulting in 920 min of clinic time savings for physicians. There were similar rates of adhering to provincial protocols for scheduling visits (99% vs. 96%, p  =  0.12) and monitoring investigations (98% vs. 98%, p  =  0.96) between those enrolled in Medication Assessment by Pharmacist or not. Surveys completed by medical oncologists and pharmacists demonstrated that nine of nine oncologists felt Medication Assessment by Pharmacist reduced workload and wanted Medication Assessment by Pharmacist expanded to additional oncology drugs. Pharmacist-completed surveys revealed that nine of nine pharmacists felt Medication Assessment by Pharmacist increased job satisfaction, and allowed further application of clinical skills. All agreed that patients were receptive to meeting with pharmacists. According to survey results, 33% of oncologists versus 100% of pharmacists routinely asked about medication adherence, new medications or supplements.</p><p><strong>Conclusion: </strong>Integrating pharmacists into a shared care model reduces ambulatory patient visits for oncologists without deviating from provincial protocol guidelines for monitoring and visits for patients on CDK 4/6 inhibitors. Leveraging the medication expertise of pharmacists also increases the frequency of addressing medication adherence and concurrent therapies. Medication Assessment by Pharmacist may be an effective strategy in alleviating projected shortages of oncology providers.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oncology Pharmacy Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10781552231179190","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/31 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The introduction of CDK 4/6 inhibitors for breast cancer patients has contributed to increased ambulatory patient visits for oncologists. The Medication Assessment by Pharmacist program aims to evaluate the impact of oncology pharmacists performing medication assessment follow-up visits.

Methods: Breast cancer patients on a CDK 4/6 inhibitor deemed suitable by their oncologist for pharmacist assessment could be booked for a pharmacist medication assessment appointment at alternate treatment cycles.

Results: Between February 2019 to November 2021, 29 of 128 patients (22.7%) were selected for 46 total Medication Assessment by Pharmacist visits resulting in 920 min of clinic time savings for physicians. There were similar rates of adhering to provincial protocols for scheduling visits (99% vs. 96%, p  =  0.12) and monitoring investigations (98% vs. 98%, p  =  0.96) between those enrolled in Medication Assessment by Pharmacist or not. Surveys completed by medical oncologists and pharmacists demonstrated that nine of nine oncologists felt Medication Assessment by Pharmacist reduced workload and wanted Medication Assessment by Pharmacist expanded to additional oncology drugs. Pharmacist-completed surveys revealed that nine of nine pharmacists felt Medication Assessment by Pharmacist increased job satisfaction, and allowed further application of clinical skills. All agreed that patients were receptive to meeting with pharmacists. According to survey results, 33% of oncologists versus 100% of pharmacists routinely asked about medication adherence, new medications or supplements.

Conclusion: Integrating pharmacists into a shared care model reduces ambulatory patient visits for oncologists without deviating from provincial protocol guidelines for monitoring and visits for patients on CDK 4/6 inhibitors. Leveraging the medication expertise of pharmacists also increases the frequency of addressing medication adherence and concurrent therapies. Medication Assessment by Pharmacist may be an effective strategy in alleviating projected shortages of oncology providers.

在加拿大一家地区性非住院癌症中心,实施并评估肿瘤学家和药剂师共同护理乳腺癌患者的模式。
背景:乳腺癌患者使用 CDK 4/6 抑制剂后,肿瘤科医生对门诊病人的访问量增加了。药剂师用药评估计划旨在评估肿瘤药剂师进行用药评估随访的影响:方法:接受 CDK 4/6 抑制剂治疗的乳腺癌患者,如果其肿瘤学家认为他们适合接受药剂师评估,则可预约药剂师在间隔治疗周期进行药物评估:2019年2月至2021年11月期间,128名患者中有29名(22.7%)被选中接受了46次药剂师用药评估,为医生节省了920分钟的门诊时间。参加或未参加药剂师用药评估的患者在遵守省级协议安排访问(99% vs. 96%,p = 0.12)和监测调查(98% vs. 98%,p = 0.96)方面的比例相似。由肿瘤内科医生和药剂师完成的调查显示,9 位肿瘤内科医生中有 9 位认为药剂师用药评估减少了工作量,并希望将药剂师用药评估扩展到更多的肿瘤药物。药剂师填写的调查显示,九名药剂师中有九名认为药剂师用药评估提高了工作满意度,并能进一步应用临床技能。所有药剂师都认为,患者乐于与药剂师会面。调查结果显示,33% 的肿瘤学家和 100% 的药剂师都会例行询问用药依从性、新药或补充剂等问题:结论:将药剂师纳入共同护理模式可减少肿瘤科医生对门诊病人的访问,同时又不会偏离省级方案指南中对使用 CDK 4/6 抑制剂的病人进行监测和访问的规定。利用药剂师的用药专业知识,还能增加处理用药依从性和并发症治疗的频率。药剂师的用药评估可能是缓解预计出现的肿瘤医疗人员短缺问题的有效策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.70
自引率
7.70%
发文量
276
期刊介绍: Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer. It is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP). Publishing pertinent case reports and consensus guidelines...
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信